Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Failed Phase III For NeoCart May Still Fly With US FDA, Histogenics Argues

Executive Summary

Agency guidance does not require coprimary, dual responder endpoint for drugs developed for knee cartilage repair, so in Histogenics' view, door is still open for approval.

You may also be interested in...



Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets

Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

In Cartilage Repair Histogenics Resets The Stage

In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel